Back to catalog
GrowthModerate evidence

CJC-1295

Growth hormone releasing hormone analog designed to elevate GH and IGF-1 with extended activity versus native GHRH.

Half-life
Days (DAC variants longer)
Administration
Subcutaneous injection (protocol-dependent)
Primary uses
GH axis support · Recovery · Body composition research

Mechanism

Binds GHRH receptors on pituitary somatotrophs, increasing pulsatile GH release and downstream IGF-1 production.

  • GH axis support
  • Recovery
  • Body composition research

Dosing ranges

Educational ranges only — not medical advice. Confirm protocols with a qualified clinician.

Use caseTypical rangeFrequencyNotes
Non-DAC research protocols100 mcg1–3× dailyOften paired with a GHRP/GHS in research settings

Clinical evidence

Moderate evidence
J Clin Endocrinol Metab · 2006

Prolonged stimulation of growth hormone by CJC-1295

Sustained GH and IGF-1 elevations after administration in healthy adults.

Cautions

  • Water retention and numbness can occur
  • Not a substitute for diagnosed GH deficiency care
  • DAC vs non-DAC formulations differ materially

Provider comparison

Affiliate-style comparison cards for clinics, telehealth, and research suppliers. Verify licensing and product quality before purchasing.

Fountain Health
telehealth
4.7
From $249/mo

Licensed clinician consult + ongoing titration support

Compare offer
PeakRx Clinic
clinic
4.5
From $189/mo

In-person labs available in select metros

Compare offer
Research Supply Co.
research
4.1
Vial pricing

Research-only sourcing — not for human consumption labeling

View listing
Growth
Moderate evidence

Ipamorelin

Selective growth hormone secretagogue with a cleaner side-effect profile than earlier GHRPs in comparative research.

GH pulse supportView research →
Growth
Moderate evidence

GHRP-6

Growth hormone releasing peptide that also strongly increases appetite — useful or limiting depending on the goal.

GH release researchView research →